NBDC Research ID: hum0327.v1

 

SUMMARY

Aims: Cancers in the hepatobiliary and pancreatic regions are not only common but also difficult to cure. Recently, it has been reported that mutant peptides newly generated by genetic mutations are recognized by the immune system as neoantigens, and the development of immunotherapy targeting these peptides has been promoted. In this study, in order to develop effective immunotherapy for hepatobiliary and pancreatic cancers and to propose it as a new cancer therapy, we will first identify different genetic mutations and antigens in each patient with these cancers, and then verify the practicality of immunotherapy using a diverse population of T cells that recognize them.

Methods: Paired fresh normal and tumor tissues were collected from surgically resected HCC and mCRC. RNA and genomic DNA were extracted from tumor/normal tissues (2–5 mm in diameter) and used for whole exome sequencing or RNA sequencing with NextSeq 550 (Illumina).

Participants/Materials: Tumor tissues were collected from liver cancer patients, who were received surgical resection at the National Cancer Center Hospital East (NCCE) between 2017 and 2020.

 

Dataset IDType of DataCriteriaRelease Date
JGAS000507 NGS (Exome, RNA-seq) Controlled-access (Type I) 2022/02/25

*Release Note

*Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more

 

MOLECULAR DATA

Exome

Participants/Materials

hepatocellular carcinoma (ICD10: C22.0): 28 cases

metastatic colorectal carcinoma (ICD10: C22.7): 18 cases

    tumor and paired non-tumor tissues

Targets Exome
Target Loci for Capture Methods -
Platform Illumina [NextSeq 550]
Library Source DNAs extracted from tumor and non-tumor tissues
Cell Lines -
Library Construction (kit name) SureSelect XT library preparation kit
Fragmentation Methods Ultrasonic fragmentation (Covaris S220)
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) 100 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000624
Total Data Volume 1.0 TB (fastq, vcf)
Comments (Policies) NBDC policy

 

RNA-seq

Participants/Materials

hepatocellular carcinoma (ICD10: C22.0): 28 cases

metastatic colorectal carcinoma (ICD10: C22.7): 18 cases

    tumor and paired non-tumor tissues

Targets RNA-seq
Target Loci for Capture Methods -
Platform Illumina [NextSeq 550]
Library Source RNAs extracted from tumor and non-tumor tissues
Cell Lines -
Library Construction (kit name) TruSeq Stranded mRNA Library prep kit, SureSelect strand specific RNA
Fragmentation Methods Ultrasonic fragmentation (Covaris S220)
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) 75 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000624
Total Data Volume 1.0 TB (fastq, tpm)
Comments (Policies) NBDC policy

 

DATA PROVIDER

Principal Investigator: Toshihiro Suzuki

Affiliation: Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center

Project / Group Name: Development of personalize neoantigen vaccine

URL: https://www.ncc.go.jp/en/epoc/division/immunotherapy/kashiwa/030/020/20170728190117.html

Funds / Grants (Research Project Number):

NameTitleProject Number
Collaboration funding from BrightPath Biotherapeutics Co., Ltd. Development of the methodology for individualized neoantigen vaccine therapy C2017-054

 

PUBLICATIONS

TitleDOIDataset ID
1 Development of antigen-prediction algorithm for personalized neoantigens vaccine using human leukocyte antigen transgenic mouse. doi: 10.1111/cas.15291 JGAD000624
2

 

USRES (Controlled-access Data)

Principal InvestigatorAffiliationCountry/RegionResearch TitleData in Use (Dataset ID)Period of Data Use
Michiaki Hamada Faculty of Science and Engineering, Waseda University Japan Construction of RNA-targeted Drug Discovery Database JGAD000624 2022/12/26-2025/03/31